Nuclear Medicine and Biology
Volume 36, Issue 1 , Pages 81-88 , January 2009

Evaluating the potential of 188Re-SOCTA–trastuzumab as a new radioimmunoagent for breast cancer treatment

  • Tsai-Yueh Luo

      Affiliations

    • Isotope Application Division, Institute of Nuclear Energy Research, P.O. Box 3-27, Longtan, Taoyuan 325, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 3 4711400x7004; fax: +886 3 4711416.
    • ,
  • I-Chang Tang

      Affiliations

    • Isotope Application Division, Institute of Nuclear Energy Research, P.O. Box 3-27, Longtan, Taoyuan 325, Taiwan
    • ,
  • Yu-Long Wu

      Affiliations

    • Isotope Application Division, Institute of Nuclear Energy Research, P.O. Box 3-27, Longtan, Taoyuan 325, Taiwan
    • ,
  • Kwel-Luen Hsu

      Affiliations

    • Isotope Application Division, Institute of Nuclear Energy Research, P.O. Box 3-27, Longtan, Taoyuan 325, Taiwan
    • ,
  • Show-Wen Liu

      Affiliations

    • Chemistry Division, Institute of Nuclear Energy Research, Taoyuan 325, Taiwan
    • ,
  • Hong-Chang Kung

      Affiliations

    • Department of Electrical Engineering, Tung Nan University, Taipei 222, Taiwan
    • ,
  • Ping-Shan Lai

      Affiliations

    • Department of Chemistry, National Chung Hsing University, Taichung 402, Taiwan
    • ,
  • Wuu-Jyh Lin

      Affiliations

    • Isotope Application Division, Institute of Nuclear Energy Research, P.O. Box 3-27, Longtan, Taoyuan 325, Taiwan

Received 18 July 2008 ,Revised 16 October 2008 ,Accepted 21 October 2008.

References 

  1. Price P. PET as a potential tool for imaging molecular mechanisms of oncology in man. Trends Mol Med. 2001;7:442–446
  2. Luo TY, Lo AR, Hsieh BT, Lin WJ. A design for automatic preparation of high concentrated 188Re-perrhenate solutions. Appl Radiat Isot. 2007;65:21–25
  3. Griffiths GL, Goldenberg DM, Knapp FF, et al. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. Cancer Res. 1991;51:4594–4602
  4. Fritzberg AR, Vanderheyden JL, Morgan AC, Schroff RW, Abrams PG. Rhenium-186/188 labeled antibodies for radioimmunotherapy. Technetium and Rhenium in chemistry and Nuclear medicine, 3rd ed. New York: Raven Press, pp. 615–621.
  5. Visser GWM, Gerretsen M, Herscheid JDM, Snow GB, van Dongen G. labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med. 1993;34:1953–1963
  6. Brouwers AH, van Eerd JEM, Frielinkn C, Oosterwijk E, Oyen WJG, Corstens FHM, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Y, or 186Re. J Nucl Med. 2004;45:327–337
  7. John E, Thakur ML, Defulvio J, McDevitt MR, Damjanov I. Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. J Nucl Med. 1993;34:260–267
  8. Meares CF, McCall MJ, Reardon DT, Goodwin DA, Diamanti CL, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 1984;142:68–78
  9. Kozak RW, Raubitschek A, Mizzadeh S, Brechbiel MW, Junghaus R, Gansow OA, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res. 1989;49:2639–2644
  10. Zirzadeh S, Brechbiel MW, Atcher RB, Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isoothiocyanatobenzyl)diethylenetriamine pentaacetic acid ligands to immunoglobulin. Bioconjugate Chem. 1990;1:59–65
  11. Zhang YM, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to anti-sense DNA. Eur J Nucl Med. 2000;27:1700–1707
  12. Decristoforo C, Mather SJ. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol. 1999;26:389–396
  13. Rubin I, Yarden Y. The basic biology of Her2. Ann Oncol. 2001;12(Suppl 1):S3–S8
  14. Salmon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  15. Press MF, Pike MC, Chazin VR, Hung VRG, Undove JA, Markowicz M, et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960–4970
  16. Baselga J, Tripathy J, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER-2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26:78–83
  17. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. First-line, single-agent trastuzumab (Herceptin) in metastatic breast cancer; a preliminary report. Eur J Cancer. 2001;37:S25–S29
  18. Tang Y, Wang J, Scolland DA, Mondal H, Holloway C, Kahn HJ, et al. Imaging of HER2/neu positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol. 2005;32:51–58
  19. Tang Y, Scolland D, Chen P, Wang J, Holloway C, Rally RM. Imaging of HER-2/neu expression in Bt-474 human breast cancer xenografts in athymic mice using 99mTc- HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun. 2005;26:427–432
  20. Li G, Wang Y, Huang K, Hui Z, Peng W, Zhang C. The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin. Nucl Med Biol. 2005;32:59–65
  21. Godwin DA. Pharmacokinetics and antibodies. J Nucl Med. 1987;28:1358–1362
  22. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bichoninic acid. Anal Biochem. 1985;150:76–85
  23. Lu SX, Takach EI, Solomon M, Zhu Q, Law SJ, Hsieh FY. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. J Pharm Sci. 2005;94:788–797
  24. Thrall JH, Freitas JE, Swanson D, Rogers L, Clare JM, Brown M, et al. Clinical comparison of cardiac blood pool visualization with technetium-99m red blood cells labeled in vivo and with technetium-99m human serum albumin. J Nucl Med. 1978;19:796–803
  25. Salacinski PRP, McLean C, Sykes JEC, Clement-Jones VV, Lowry PJ. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro- 3α, 6α-diphenylglycoluril: application to the assay of protein in the presence of thiol reagents. Anal Biochem. 1981;112:278–281
  26. Lever SZ, Burns HD, Kervitsky TM, Goldfarb HW, Woo DV, Wong DF, et al. Design, preparation, and biodistribution of a technetium-99m triaminethiol complex to assess regional cerebral blood flow. J Nucl Med. 1985;26:1287–1294
  27. O'Neil JP, Wilson SR, Katzenellenbogen JA. Preparation and structural characterization of monoamine-monoamide bis(thiol) oxo complexes of technetium(V) and rhenium(V). Inorg Chem. 1994;33:319–323
  28. Verbeke K, Kieffer D, Vanderheyden JL, Reutelingsperger C, Steinmetz N, Green A, et al. Optimization of the preparation of 99mTc-llabeled Hynic-derivatized Annexin-V for human use. Nucl Med Biol. 2003;30:771–778
  29. Lee YS, Jeong JM, Kim YJ, Chang YS, Lee HJ, Son M, et al. Development of acetylated HDD kit for preparation of 188Re-HDD/Lipiodol. Appl Radiat Isot. 2007;65:64–69
  30. Zhung ZP, Kung MP, Hou C, Ploessl K, Kung HF. Biphenyls labeled with technetium 99m for imaging β-amyloid plaques in the brain. Nucl Med Biol. 2005;32:171–184
  31. Dezutter NA, Dom RJ, de Groot TJ, Bormans GM, Verbruggen AM. 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease. Eur J Nucl Med. 1999;26:1392–1399
  32. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 100,000 Daltons. Anal Chem. 1988;60:2299–2301
  33. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825–2831
  34. Geissler F, Andersin SK, Press O. Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Cell Immunol. 1991;137:96–110
  35. Hopkins CR, Trowbridge IS. Internationalization and processing of transferring and the transferring receptor in human carcinoma A431 cells. J Cell Biol. 1983;97:508–521
  36. Deutsch E, Libson K, Vanderheyden JL. In:  Nicolini M,  Bandoli G,  Mazzi U editor. The inorganic chemistry of technetium and rhenium as relevant to nuclear medicine. 3rd ed.. New York: Raven Press; 1990;p. 13–22

PII: S0969-8051(08)00234-5

doi: 10.1016/j.nucmedbio.2008.10.014

Nuclear Medicine and Biology
Volume 36, Issue 1 , Pages 81-88 , January 2009

Article Tools

* Image Usage & Resolution